Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
266 articles with Protalix Biotherapeutics, Inc.
-
Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors
6/30/2022
Protalix BioTherapeutics, Inc., announced that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors.
-
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
5/26/2022
Protalix BioTherapeutics, Inc. announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities.
-
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
5/16/2022
Protalix BioTherapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided a business update on recent corporate and clinical developments.
-
Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022
5/9/2022
Protalix BioTherapeutics, Inc. announced that it will release its financial results for the first quarter 2022 and provide a business update on Monday, May 16, 2022.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
4/4/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa, 1 mg/kg, administered every two weeks, compared to agalsidase beta for the treatment of Fabry disease.
-
Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here's more about it.
-
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
3/31/2022
Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2021 and provided a business update on recent corporate and clinical developments.
-
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022
3/24/2022
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for fiscal year 2021 and provide a business update on Thursday, March 31, 2022.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
3/18/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa for the potential treatment of Fabry disease.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
2/24/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases today announced the submission of a Marketing Authorization Application (MAA) via centralized procedure to the European Medicines Agency (EMA) for pegunigalsidase alfa (PRX–102),
-
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
2/3/2022
Protalix BioTherapeutics, Inc. announced that there will be two poster presentations regarding the Company's pegunigalsidase alfa or PRX–102 candidate under development for the treatment of Fabry disease at the 18th Annual WORLDSymposium™ 2022, taking place February 7-11, 2022 at the Manchester Grand Hyatt in San Diego, California.
-
Protalix BioTherapeutics Issues 2021 Letter to Stockholders
12/22/2021
Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.
-
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
11/15/2021
Protalix BioTherapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.
-
Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021
11/8/2021
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2021 and provide a financial and business update on Monday, November 15, 2021.
-
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
10/11/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases provided a regulatory update regarding pegunigalsidase alfa for the proposed treatment of Fabry disease which included an announcement of the receipt of the official Type A meeting minutes from the U.S. FDA regarding the Complete Response Letter received for the PRX–102 Biologics License Application confirming a potential pathway for resubmission of a BLA for PRX–102.
-
Protalix BioTherapeutics Announces Closing of Private Note Exchange
8/26/2021
Protalix BioTherapeutics, Inc. today announced that it has completed exchanges (the "Exchanges") of the Company's outstanding 7.50% Senior Secured Convertible Notes due 2021 (the "2021 Notes") with institutional note holders of a substantial majority of the 2021 Notes.
-
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update
8/16/2021
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the second quarter ended June 30, 2021 and provided a financial and business update.
-
Protalix BioTherapeutics Announces Private Note Exchange - Aug 13, 2021
8/13/2021
Protalix BioTherapeutics, Inc. announced the entry into definitive agreements relating to exchanges of an aggregate of $54.65 million principal amount of the Company's outstanding 7.50% Senior Secured Convertible Notes due 2021 for an aggregate of $28.75 million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, $25.90 million in cash, and accrued and unpaid interest through the closing date.
-
Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021
8/9/2021
Company to host conference call and webcast at 8:30 a.m. EDT